China weighing on the share price maybe ? |
On Wednesday, BMO Capital maintained a positive outlook on shares of AstraZeneca (NASDAQ:AZN) shares, reiterating an Outperform rating and a price target of $89.00. The firm's stance comes in the wake of AstraZeneca's investor event, which took place yesterday, following the company's presentations at the World Lung Conference.
Erste Group analyst Hans Engel upgraded AstraZeneca to Buy from Hold citing strong sales growth for the company’s oncology products. AstraZeneca’s operating margin and sales growth are above the sector average and its operating margin shows an upward trend, the analyst tells investors in a research note. The firm says the company’s profits will grow at an above-average rate this year and also in 2025. |
Maybe time to top up?
Long term, maybe a wise move? |
"Astra faces a Chinese burn as Beijing puts Soirot to the test, says ALEX BRUMMER"
Daily Mail |
Cambridge-based AstraZeneca said datopotamab deruxtecan, or Dato-Dxd, failed to reach ‘statistical significance’ for overall survival in patients with metastatic non-small cell lung cancer.
Swiss bank UBS cut its ‘probability of success for Dato-DXd’ to treat the form of cancer.
‘Following the disappointing OS data, we see clear risks to approval for Dato-DXd in 2nd line NSCLC, with an FDA [advisory committee] now highly likely. We lower our probability of success from 80% to 40%,’ UBS added. |
More detail in this report.
The Guardian
China detains five AstraZeneca staff over ‘data privacy and import breaches’ |
Market report
AstraZeneca fell 2.7%.
AstraZeneca told the Financial Times that a ‘small number’ of its employees are under investigation by police in China, following a report they had been detained over possible infringement of data privacy laws and importing unlicensed medications.
Police in Shenzhen have detained five current and former employees over the collection of patient data and the distribution of a liver cancer drug that had not been approved in the country, Bloomberg reported earlier on Thursday. |
Uncertainty........ Not good. |
You never know how these investigations will fall out.
It is said to relate to an unapproved liver cancer drug….which you think would be an isolated set of circumstances….but with China, there is always the prospect of a political crackdown of some sorts…..it will take time to see whether there are any consequences for the company. |
News says AZN employees under investigation in China for potential illegal acts. |
We've had a very good run recently.
Suet |
Goldman Sachs raises AstraZeneca price target to 15,914 (15,756) pence - 'buy' |
Second round of inflation coming?... |
That's because they are envious & resentful of those who work hard and save to better themselves.
Always been the way.
Energy bills up 10% in October
Taxes to be raised in October budget - ones to hit those multi millionaires (many of whom have left, or are leaving) and the burden will once again fall on the middle classes. |
I just hope that a compromise can be made.
Labour just seem hell bent on punishing anybody who has anything.
Can't wait for the budget!
Suet |
Financial Times:
AstraZeneca has warned it could relocate its vaccine manufacturing site from Merseyside to Philadelphia after the government weighs plans to cut state aid promised to the project |
The Telegraph
Questor: This pharma giant is set to beat FTSE 100 during bull and bear markets
Questor says: buy
Ticker: AZN
Share price (GBP): 13,102p |
They are advancing the obesity pill to phase 2 so they think it works good enough... the CEO at one stage said they are planning to sell it at a cheap and cheerful price to appeal to casual weight losers |
AstraZeneca shares hit a record high as US fast-tracks its blockbuster cancer drug Imfinzi
Daily Mail |
Blow to AstraZeneca vaccine project as Reeves plans funding cuts
Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant |
Indeed :-) |
And it is . |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
